Clearmind Medicine Inc. has announced the successful completion of patient enrollment for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, an MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD). The trial, which is being conducted across Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Dosing for the second cohort is expected to begin shortly, with topline results anticipated in the coming months. Results from the first cohort have already been presented, showing a favorable safety profile and preliminary signals of reduced cravings and withdrawal symptoms.